SCHEMBL7138016

SCHEMBL7138016

COC(=O)c1ccc(N(C)C(=O)CN(C)C(=O)[C@@H]2C[C@@H](SC(C)=O)CN2S(=O)(=O)c2cccc3cccnc23)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
GAA P10253 4/20 0.41
POLB P06746 2/20 0.41
TP53 P04637 2/20 0.40
HPGD P15428 1/20 0.39
TSHR P16473 5/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 2/20 0.37
HSP90AA1 P07900 1/20 0.37
GFER P55789 2/20 0.37
HSD17B10 Q99714 1/20 0.37
HCRTR1 O43613 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7138019 1.00 ALDH1A1 (0.44) ALDH1A1GAAPOLBTP53HPGD
SCHEMBL7144467 0.88 MME (0.38) LMNAHCRTR1KMT2A
SCHEMBL7139459 0.88 MME (0.38) LMNAHCRTR1KMT2A
SCHEMBL7145372 0.88 MME (0.46) ALDH1A1GAAPOLBTP53HPGD
SCHEMBL7145369 0.88 MME (0.46) ALDH1A1GAAPOLBTP53HPGD
SCHEMBL7143826 0.88 ALDH1A1 (0.46) ALDH1A1GAAPOLBTP53HPGD
SCHEMBL7135094 0.84 MME (0.41) ALDH1A1GAATSHRKMT2ASMN1; SMN2
SCHEMBL7148903 0.84 MME (0.41) ALDH1A1GAATSHRKMT2ASMN1; SMN2
SCHEMBL7135260 0.83 MME (0.35) ALDH1A1GAALMNAHCRTR1KMT2A
SCHEMBL7135263 0.83 MME (0.35) ALDH1A1GAALMNAHCRTR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885GAA 130/4885POLB 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.